CN1380414A - 重组人ⅱ型胶原功能性多肽cⅱ250-270及其制备方法和用途 - Google Patents
重组人ⅱ型胶原功能性多肽cⅱ250-270及其制备方法和用途 Download PDFInfo
- Publication number
- CN1380414A CN1380414A CN 02114453 CN02114453A CN1380414A CN 1380414 A CN1380414 A CN 1380414A CN 02114453 CN02114453 CN 02114453 CN 02114453 A CN02114453 A CN 02114453A CN 1380414 A CN1380414 A CN 1380414A
- Authority
- CN
- China
- Prior art keywords
- cii250
- functional polypeptide
- recombinant human
- collagen type
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 7
- 102000008186 Collagen Human genes 0.000 title abstract description 10
- 108010035532 Collagen Proteins 0.000 title abstract description 10
- 229920001436 collagen Polymers 0.000 title abstract description 9
- 108010005636 polypeptide C Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 29
- 229920001184 polypeptide Polymers 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims abstract description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 8
- 239000013613 expression plasmid Substances 0.000 claims abstract description 4
- 239000013612 plasmid Substances 0.000 claims abstract description 4
- 102000002734 Collagen Type VI Human genes 0.000 claims description 15
- 108010043741 Collagen Type VI Proteins 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 11
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 238000005267 amalgamation Methods 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 3
- 101150093672 pcl gene Proteins 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000011764 rheumatoid arthritis animal model Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 206010003246 arthritis Diseases 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 206010036030 Polyarthritis Diseases 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract description 2
- 208000030428 polyarticular arthritis Diseases 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 238000012270 DNA recombination Methods 0.000 abstract 1
- 230000006820 DNA synthesis Effects 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 238000012407 engineering method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 210000000468 rubriblast Anatomy 0.000 abstract 1
- 239000000047 product Substances 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 206010039361 Sacroiliitis Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101710142847 Glutathione S-transferase class-mu 26 kDa isozyme Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101100101253 Rattus norvegicus Th gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021144532A CN100398650C (zh) | 2002-03-01 | 2002-03-01 | 重组人ⅱ型胶原功能性多肽cⅱ250-270及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021144532A CN100398650C (zh) | 2002-03-01 | 2002-03-01 | 重组人ⅱ型胶原功能性多肽cⅱ250-270及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1380414A true CN1380414A (zh) | 2002-11-20 |
CN100398650C CN100398650C (zh) | 2008-07-02 |
Family
ID=4743108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021144532A Expired - Fee Related CN100398650C (zh) | 2002-03-01 | 2002-03-01 | 重组人ⅱ型胶原功能性多肽cⅱ250-270及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100398650C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115819557A (zh) * | 2022-10-09 | 2023-03-21 | 胶原蛋白(武汉)生物科技有限公司 | 一种三螺旋重组人源化ⅱ型胶原蛋白、制备方法及应用 |
-
2002
- 2002-03-01 CN CNB021144532A patent/CN100398650C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115819557A (zh) * | 2022-10-09 | 2023-03-21 | 胶原蛋白(武汉)生物科技有限公司 | 一种三螺旋重组人源化ⅱ型胶原蛋白、制备方法及应用 |
CN115819557B (zh) * | 2022-10-09 | 2024-06-07 | 胶原蛋白(武汉)生物科技有限公司 | 一种三螺旋重组人源化ⅱ型胶原蛋白、制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100398650C (zh) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014336815B2 (en) | Fusion protein of ganoderma lucidum immunoregulatory protein and human serum albumin, and production method therefor and uses thereof | |
CN115772228A (zh) | 酵母表面展示的鸭干扰素融合蛋白及其应用 | |
CN1831012A (zh) | 一种免佐剂具有防治人胰岛素依赖型糖尿病作用的免疫调节剂 | |
CN1380414A (zh) | 重组人ⅱ型胶原功能性多肽cⅱ250-270及其制备方法和用途 | |
CN101060857A (zh) | 药物 | |
CN1062565C (zh) | 重组人α型复合干扰素及其制备方法和用途 | |
CN1210306C (zh) | 平颏海蛇短链神经毒素以及编码该毒素的基因 | |
CN102180962B (zh) | 黑青斑河鲀干扰素IFNγ1及其制备方法和应用 | |
CN1164331C (zh) | 一种人乙型肝炎核酸疫苗 | |
CN101875691B (zh) | 蝎镇痛抗肿瘤缬精甘肽突变体及其制备方法 | |
CN101125883A (zh) | 重组vpac1受体特异激动剂rvpac1-a及其表达方法与应用 | |
CN113004424B (zh) | 猪白细胞介素17和22共表达替抗生物制剂的制备及应用 | |
CN101544693A (zh) | 重组胸腺素α1二串体蛋白及其制备方法 | |
CN1861635A (zh) | 人胰高血糖素相关肽-2类似物 | |
CN108997488B (zh) | 具有抗乳腺癌活性的间斑寇蛛卵粒蛋白质及其制法与应用 | |
CN1386754A (zh) | 非t细胞结合肽及其用途 | |
CN1534097A (zh) | 中国对虾热休克蛋白70基因及其克隆方法 | |
CN101544981A (zh) | 一种具有降血糖生物活性的苦瓜多肽基因工程制备方法及应用 | |
CN1168831C (zh) | 一种重组人b淋巴细胞刺激因子表达载体的构建、dna免疫制备单克隆抗体及其应用 | |
CN101824388A (zh) | 一种糖尿病食疗酵母及其构建方法 | |
CN1948493A (zh) | 一种乙型肝炎病毒疫苗增效蛋白及其基因 | |
CN108586597A (zh) | 鱼类促摄食成熟肽及其应用 | |
CN100549025C (zh) | 一种胸腺五肽与匹多莫德的生成物七肽及合成方法 | |
CN1176946C (zh) | 一种新型α干扰素 | |
CN103183734B (zh) | 含有非天然氨基酸的突变蛋白及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: THE 4TH MILITARY SURGEON UNIV. P. L. A. Free format text: FORMER OWNER: ZHU PING Effective date: 20140915 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140915 Address after: 710032 Changle West Road, Shaanxi, China, No. 169, No. Patentee after: The Fourth Military Medical University of the Chinese People's Liberation Army Address before: 710032 Department of clinical immunology, Xijing Hospital, 17 West Changle Road, Shaanxi, Xi'an Patentee before: Zhu Ping |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080702 Termination date: 20170301 |
|
CF01 | Termination of patent right due to non-payment of annual fee |